Document is current
Any future updates will be listed below
-
Authors
Leo, Patrick https://orcid.org/0000-0002-2248-0610
Janowczyk, Andrew
Elliott, Robin
Janaki, Nafiseh
Bera, Kaustav https://orcid.org/0000-0001-9831-6000
Shiradkar, Rakesh https://orcid.org/0000-0003-2852-3869
Farré, Xavier https://orcid.org/0000-0001-8702-4643
Fu, Pingfu https://orcid.org/0000-0002-2334-5218
El-Fahmawi, Ayah
Shahait, Mohammed
Kim, Jessica
Lee, David https://orcid.org/0000-0003-2133-9284
Yamoah, Kosj https://orcid.org/0000-0001-9055-3538
Rebbeck, Timothy R.
Khani, Francesca https://orcid.org/0000-0001-7238-8604
Robinson, Brian D. https://orcid.org/0000-0001-5374-890X
Eklund, Lauri
Jambor, Ivan
Merisaari, Harri
Ettala, Otto
Taimen, Pekka https://orcid.org/0000-0001-8849-4604
Aronen, Hannu J.
Boström, Peter J.
Tewari, Ashutosh https://orcid.org/0000-0002-3146-4524
Magi-Galluzzi, Cristina
Klein, Eric https://orcid.org/0000-0002-1783-0698
Purysko, Andrei
NC Shih, Natalie
Feldman, Michael
Gupta, Sanjay
Lal, Priti
Madabhushi, Anant https://orcid.org/0000-0002-5741-0399
- License Information
-
More Information
Article History
Received: 20 August 2020
Accepted: 5 April 2021
First Online: 3 May 2021
Competing interests
: A.J. has reported a consulting or advisory role with Merck. M.F. has reported consulting fees from Philips Digital Pathology. A.M. has reported being an equity holder in Elucid Bioimaging and in Inspirata Inc. In addition, he has served as a scientific advisory board member for Inspirata Inc, AstraZeneca, Bristol Meyers-Squibb, and Merck. Currently, he serves on the advisory board of Aiforia Inc. He also has sponsored research agreements with Philips, AstraZeneca, Boehringer-Ingelheim, and Bristol Meyers-Squibb. His technology has been licensed to Elucid Bioimaging. He is also involved in an NIH U24 grant with PathCore Inc, and 3 different R01 grants with Inspirata Inc. The remaining authors declare no competing interests.
